Wednesday, 20 June 2018 - 13:50
  • it
  • de
  • en
  • fr

M&A

Roche acquires full property of Foundation Medicine for $2.4bn

Switzerland-based Roche announced in a press release, before trading started in Europe, that it has completed the acquisition of Foundation Medicine (FD), of which it had acquired a majority stake (57%) over three years ago. Specifically, Roche has paid $2.4bn…

Coca Cola, Nestle and Kraft Heinz in talks with GSK

UK-based The Sunday Telegraph has reported today that The Coca-Cola Company, Kraft Heinz and Nestle have started negotiating with GlaxoSmithKline in order to acquire Horlicks. GSK last March informed the financial community that it was planning to dismiss the Horlicks…

Pfizer could seek acquisition in NASH business

Alongside the Health & Biotechnology Summit held in New York last week, rumors were circulated that Pfizer could be seeking to acquire assets in the Non-Alcoholic Steatohepatitis (NASH) business. NASH is nowadays among the most widespread conditions in the US…

NASH sector heats up

Bloomberg yesterday reported that biotech Madrigal Pharmaceuticals  is weighing a sale after some early talks with large pharmaceutical groups. The news has made Madrigal’s shares jump by over 150% in the last month. Madrigal is a biotech based in Pennsylvania,…

Sanofi to sell Recipharm CMO business in UK for GBP54m

France-based Sanofi has sold to Sweden-based Recipharm AB its CMO business in UK, including the Manchester, UK-based Holmes Chapel manufacturing site, focusing on products for the respiratory drug market. The division yielded a revenue of  GBP51m over the last 12…

Johnson & Johnson receives $2.1bn offer for Lifescan

Johnson & Johnson has announced today after trading had closed that it had received an acquisition offer by private equity Platinum Equity for Lifescan products. Lifescan is the leading brand in the blood sugar meters and Platinum Equity has valued…

New takeover for Recordati: acquires Natural Point

Italian drugmaker Recordati has announced today that it has acquired Natural Point Srl. The acquired company is headquartered in Milan and delivered revenues of €15m in 2017, with €10m EBITDA (66%), by marketing nutraceuticals such as magnesium carbonate and citric acid….

Fortive offers $2.8bn for Johnson & Johnson’s ASP unit

US-based Johnson & Johnson has announced that the industrial Fortive Corp Group has submitted a $2.8bn bid–all in cash–to acquire  Advanced Sterilization Products (ASP) unit, which produces solutions to prevent infections in hospitals and other health units. ASP generated sales…

Recordati family reportedly weighing sale of controlling stake

The Recordati family is allegedly weighing a sale of its stake in the Recordati pharmaceutical group–51%–and its most probable buyers are private equities Cinven and Bain Capital.  The family made a first attempt at selling the company to a Chinese…

NTC acquires part of Novartis’ ophthalmic portfolio

Italy-based pharmaceutical group NTC has acquired part of Novartis’ ophthalmic portfolio for the Spanish, Portuguese, Italian and Polish markets. The acquired products include  Colircusi Gentadexa (aminoglycoside), Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside), Oftalmolosa Cusi Erythromycin (macrolide), Oftalmolosa Cusi Aureomycin…

Olivier Brandicourt discloses new details about Sanofi’s new deal

Oliver Brandicourt, Sanofi CEO, has surprised analysts by announcing that his group is weighing new acquisitions. Indeed, Brandicourt has said in an interview to Bloomberg he is not aiming to acquire Pfizer’s Consumer Health division, instead he would prefer focusing…

Myriad Genetics acquires Counsyl for $375m

Myriad Genetics some hours ago announced that it has acquired for $375m Counsyl, a company that develops and markets non-invasive screening systems to determine whether fetuses risk to develop  genetic diseases. Myriad Genetics–headquartered in Salt Lake City-is a leader in…

China’s Hebei Jianxi targets part of Switzerland’s PIQUR Therapeutics

Swiss daily Neue Zürcher Zeitung yesterday evening reported that  Basel-based drugmaker PIQUR Therapeutics has received an offer by the China-based group Hebei Jianxi, targeting part of the company. The article reports a statement by chairman Richard Laube, who has confirmed…

Perrigo and Reckitt Benckiser targeting Aspen Pharmacare’s unit ($1.5bn)

South Africa-based Aspen Pharmacare is looking for buyers of its infant formula division and has reportedly already drawn interest by Perrigo, Reckitt Benckiser, iNova and Lactalis groups. As previously reported, also China-based groups Health & Happiness, Beingmate Baby & Child…

Zoetis acquires Abaxis for $2bn

Parsippany (NJ)-based group Zoetis has announced today that it has acquired California-based Abaxis for $2bn, that is $83 per share, strengthening its position in veterinary diagnostics–a business which is growing with a 10% CAGR (2015-2018). Abaxis, which has 580 employees…

Unstoppable Eli Lilly: AurKa Pharma acquired for $575m

US-based pharmaceutical group Eli Lilly seems unstoppable in M&A–after informing on Thursday that it had acquired Armo Bioscience for $1.6bn, it has announced today a new deal. Indeed, shortly before Wall Street opened, the Indianapolis-based group announced it has acquired…

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

A list of likely buyers of Novartis’ US dermatology generics division, valued at an approximate $2bn, is now drawn up, Bloomberg has reported. The list includes China-based Shanghai Fosun Pharmaceutical, Apollo Global Management, CVC Capital Partners and India-based Aurobindo Pharma. …

Saint Gobain renounces to acquire Sika but buys 10% stake

Saint-Gobain and Sika have announced today a complex agreement through which Saint Gobain has renounced to acquire the Switzerland-based competitor. As part of the agreement, Saint Gobain will purchase €3.22bn in shares currently owned by the Burkhard family and will…

Aurobindo offers $1.6bn for Sandoz-Novartis’ dermatology (generics) division

India-based Aurobindo Pharma (Hyderabad) has offered $1.6bn for Sandoz’s unit manufacturing and marketing dermatology generics. Other investors are targeting Sandoz’s asset, including pharmaceutical companies and private equities, Livemint has reported. The deadline set by Sandoz to submit offers is June…

Renewed speculation on Pfizer targeting AstraZeneca

AstraZeneca’s shares yesterday resumed an upward trend (London) as Streetinsider suggested that Pfizer could attempt a takeover to the UK-based group AstraZeneca. Many  analysts think that Pfizer is pursuing a major acquisition and companies such as Shire, Allergan, BMS and–more…

Lundbeck to pursue M&A again soon

Denmark-based Lundbeck may soon sign a new acquisition agreement, after taking over Prexton Therapeutics two months ago for $905m. The group is apparently targeting companies with candidates still undergoing the early stages of clinical trials, intended to treat central nervous…

Fresenius abandons $4.3bn acquisition of Akorn

Fresenius has announced today what everyone dreaded. The Bad Homburg (Frankfurt)-based group has informed in a press release it will terminate the program to acquire the US-based Akorn. Fresenius has stated that there are no guarantees for an acquisition, since…